Find Your Match

Why your tech company should partner with forward-thinking Chile

Your next game-changing parter might be in Chile. Photo by Klaus Vedfelt/Getty

What's one of the most important ways a tech company can ensure success? Collaboration. Finding that perfect fit with a like-minded partner just might change the world — but first you have to find each other.

For many U.S.-based companies, their next great collab could be Chile. The South American country has recently been attracting the attention of big-name players such as Jeff Bezos, all based off its growing IT presence and expansion in the HealthTech, FinTech, EdTech, and RetailTech sectors.

But you don't have to actually travel to Chile to meet possible partners.

Chile Connected, sponsored by ProChile, is a nearly month-long virtual event designed to serve as a "matchmaker" for technology firms as well as creative industries, healthy food providers, and women-led businesses. And it's completely free to attend.

On October 27-29, the tech and innovation panel will welcome high-level experts and keynote speakers from both Chile and the U.S.

You'll hear from top-level execs at rapidly growing companies like biotech start-up GenoSUR and magnetics surgery pioneer Levita, both Chilean-based with American partnerships. Levita founder Alberto Rodriguez-Navarro will share the stage with GenoSUR's commercial manager Daniela Mendoza, along with a representative from CIC Health, which is innovating in COVID-19 rapid testing.

You also get to network and make new connections, hopefully leading to a successful partnership.

Most Chilean companies — 53 percent, in fact — are looking for a joint venture or capital to grow into other markets. U.S. companies then get the opportunity to select those which best suit their needs or have the most potential, as well as purchase up-and-coming software and other tech products at a very competitive price.

Chile has been regularly investing not only money but also resources and programs to support new startups and companies. Start-up Chile is one such accelerator that has vowed to invest $80,000 in an American start-up that will create and develop its idea in Chile.

So the money, know-how, and support are just waiting in Chile for the American businesses to come find it, and Chile Connected is where you can get started. Reserve your free spot for the event here.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News